Calithera buys itself a plan B
With telaglenastat facing a risky trial readout Calithera picks up two bargain-basement oncology projects to pivot to.
Treme climbs a new mountain
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
Crispr’s reminder about allogeneic Car-T redosing
Crispr follows Allogene with backing for off-the-shelf Car-T therapy – and adds big concerns over lack of durability.
Triple meeting – low-profile assets boost Merus and Bicycle
Merus regains some lost pride while Bicycle rides to even greater heights.
Triple meeting – early data give and they take away
Turning Point and Repare are left nursing heavy losses, while Relay just about weathers a storm.
Allogene raises the spectre of a Car-T nightmare
Little is known about yesterday’s clinical hold on Allogene’s entire pipeline, but chromosomal abnormalities hint at a worst-case scenario.
Springworks seeks cancer win as a prelude to something bigger
The young biotech is well placed to deliver its first pivotal win, but investor focus might lie elsewhere.
Biotech listings show signs of a slowdown
2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.
